PLANTATION, Fla., March 27 /PRNewswire-FirstCall/ -- Viragen, Inc. and its majority-owned subsidiary, Viragen International, Inc. , today announced that Acta Oncologica, a leading journal in clinical oncology, has accepted to publish an article profiling Multiferon(R) (multi-subtype, natural human alpha interferon) in the adjuvant treatment of high-risk (Stages IIb-III) malignant melanoma.
The article will report on the use of Multiferon(R) following dacarbazine (DTIC) in a clinical trial that demonstrated a statistically significant advantage over untreated controls in terms of distant-metastases-free survival and overall survival. It is expected to be published this summer.
About Acta Oncologica:
Published eight times per year, Acta Oncologica is one of the leading journals in clinical oncology and related disciplines, and accepts articles within all fields of clinical cancer research from applied basic research to cancer nursing and psychological aspects of cancer. It is the official journal of the five Nordic oncological societies, and the members of the editorial committee represent these societies.
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a biotechnology company engaged in the research, development, manufacture and commercialization of pharmaceutical proteins for the treatment of viral diseases and cancers. Our product portfolio includes: Multiferon(R) (multi- subtype, natural human alpha interferon) targeting a broad range of infectious and malignant diseases; and humanized monoclonal antibodies targeting specific antigens over-expressed on many types of cancers. We are also pioneering the development of Avian Transgenic Technology, with the renowned Roslin Institute, as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies.
For more information, please visit: http://www.Viragen.com Viragen, Inc. Corporate Contact: Douglas Calder, Director of Communications Phone: (954) 233-8746; Fax: (954) 233-1414 E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company’s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. Acta Oncologica reserves the right to change the timing and/or content for planned future publications.
Photo: http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-bAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comViragen, Inc.
CONTACT: Douglas Calder, Director of Communications, Viragen, Inc.,+1-954-233-8746, or fax, +1-954-233-1414, or dcalder@viragen.com
Web site: http://www.viragen.com/